Pharma's Market
SPECIAL REPORT
MOST SHARED
- Carl Icahn Increases Stake in Chesapeake, Demands Board Seats
- Citigroup Lost $20 Million on Facebook IPO Trades
- Europe Has Wall Street's Bull on a Short Leash
- Romney Leads Poll Of Small Business Owners
- Marc Faber: 100% Chance of Global Recession
- Astronauts Snare SpaceX Rocket
- The Key to a Successful Turnaround
- Judge Says Skilling Can Seek New Trial
- Facebook: The Song — Yes, We're Serious
- Bacon Tourism: From the Davos of Bacon to Bacon Mecca
- A New Look at the ‘New Poor’
- Six Pack: Beer Buzz of the Week
- Greek Exit Could Trigger 50% Fall in Euro Stocks: Analyst
- Under Pressure, FHA Skews to Wealthier Home Buyers
- Big Stock Upside for Hudson City Deal: Analyst
- 5 High-Yield Stocks Ready to Boost Dividends
- Yoshikami: Four Things You Need to Know About Gold Now
- Steinbock: The Euro Zone Endgame Begins
- Option Bulls Take Another Shot on Idenix
- Citigroup Lost $20 Million on Facebook IPO Trades
- Sticker Shock: What College Is Likely to Cost in 18 Years
- Marc Faber: Chance of Global Recession Is Now 100%
- Icahn Raises Stake in Chesapeake, Wants Board Seats
- Week Ahead: Europe Has Wall Street Bull on Short Leash
- What Happened to Stocks? Most Unloved in 50 Years
- Cool Jobs: From Gold Stacker to Bed Tester
- Many Greeks Moved Their Money Abroad Long Ago
- China, US, Japan Also Have Work to Do: EU's Barroso
RSS FEED
Merck And Schering Plough: "Enhancing" A Franchise?
Text Size 
Reporter
 |
ENHANCE compares Merck [MRK
Loading...
()
] and Schering-Plough's [SGP
Loading...
()
] cholesterol fighter Vytorin (a combo of MRK's Zocor and Schering-Plough's Zetia) with Zocor alone. Zocor is also known as simvastatin and has gone generic. "The New York Times" has done a few stories in recent weeks about doctors who've been growing increasingly skeptical about the results because the companies had not released them yet. MRK and SGP officials had said they didn't know the outcome at the time.
Anyway, in the press release the companies say, "There was no statistically significant difference between (the) treatment groups on the primary endpoint."
Primary endpoint is clinical-speak for "main goal" of the study. So, in other words, Vytorin's essentially no better than Zocor alone. Some headlines are characterizing the study as a "failure." In mid-morning trading, both stocks are down but SGP is taking the brunt of the damage.
Miller Tabak healthcare analyst Les Funtleyder writes in a research note to clients this morning why that appears to be the case. "MRK has more than enough pipeline to in-line products to overcome some marketing challenges to Vytorin," he says.
Bernstein's Tim Anderson writes, "Results look benign relative to expectations." And he points out that Vytorin showed a "minor" liver-safety edge. While Goldman Sachs' Jim Kelly says, "ENHANCE trial nonevent. (And) we believe that this result does not represent a relevant difference for assessing the commercial prospects for Vytorin."
Bernstein owns at least one percent of MRK and SGP. GS has done and wants to do more investment banking for both companies and makes a market in both of their stocks.
The companies will present details of the study at the American College of Cardiology conference in March.
French say "Oui" to Merck's Gardasil
Meantime, to use a tired cliche, Merck coincidentally got a shot in the arm from France today. The business newswires report that French health officials are choosing Merck and Sanofi-Aventis' [SNY
Loading...
()
] cervical cancer vaccine Gardasil over Cervarix from the European GlaxoSmithKline [GSK
Loading...
()
] . As I've blogged many times before, Gardasil is a roaring success in the U.S. GSK recently announced a delay in winning FDA approval of the vaccine in the States.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes
